checkAd

     313  0 Kommentare Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18 - Seite 3

    On Behalf of the Board,
    Terrence W. Norchi, MD
    Arch Therapeutics, Inc.

    Lesen Sie auch

    Contact:

    ARTH Investor Relations
    Toll Free: +1-855-340-ARTH (2784) (US and Canada)
    Email: investors@archtherapeutics.com
    Website: www.archtherapeutics.com

    or

    Richard Davis
    Chief Financial Officer
    Arch Therapeutics, Inc.
    Phone: 617-431-2308
    Email: rdavis@archtherapeutics.com
    Website: www.archtherapeutics.com


    Seite 3 von 3
    Verfasst von Marketwired
    Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18 - Seite 3 WELLESLEY, MA--(Marketwired - Sep 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding during surgery, announces that co-founder, inventing …